Executive Profiles

Michael E. Wiebe, Vice President, Quality joined IDEC in July 2001.For the past three years, Dr. Wiebe was Chief Scientific Officer of BioReliance Corporation in Rockville, MD. Prior to that, he was Senior Director, Quality Control of Genentech, Inc. During his tenure at Genentech Dr. Wiebe served on the project team that oversaw development of Rituxan®, the first monoclonal antibody approved for the treatment of cancer in the United States.

IDEC and Genentech developed Rituxan and co-promote it in the U.S. Dr. Wiebe received a Ph.D. in Microbiology from the University of Kansas in Lawrence, Kansas, in 1971 and a B.S. in Mathematics in 1965 from Sterling College in Sterling, Kansas.